Metabolites and Safety, the MIST and ICH-M3 GUIDANCE and their Impact on ADME Gerhard Gross, Lundbeck Pharma, speaking at ADME & Predictive Toxicology Europe 2012
Emerging Outsourcing Destinations Pharmas Strategies and Growth Drivers Dr Jim J. Zhang, JZMed, Inc., speaking at Discovery Chemistry Congress 2012.
In Vitro, Ex Vivo and in Models to Develop New Therapies for Renal Diseases Frederick W. K. Tam, Imperial College London, speaking at ADME & Predictive Toxicology Europe 2012
Biotransformation: Still a Bottleneck for in Vitro Kinetic and Dynamic Approaches Sandra Coecke, European Centre for the Validation of Alternative Methods, speaking at ADME & Predictive Toxicology Europe
In Silico Toxicology: Where are We at and Where are We Going? John C. Dearden, Liverpool John Moores University, speaking at ADME & Predictive Toxicology Europe 2012
Outsourcing Chemical Synthesis in the Drug Discovery Process Gunter Festel, Autodisplay Biotech, speaking at Discovery Chemistry Congress 2012
When is a Genotoxin not a Genotoxin? Richard Walmsley, University of Manchester, speaking at ADME & Predictive Toxicology Europe
miRNA Replacement Therapy in Cancer through Polyplex-Mediated miRNA Delivery In Vivo Professor Achim Aigner, Institute of Pharmacology / bpc, Philipps-University Marburg, speaking at RNAi Europe 2011.
EU Regulatory Landscape for Approval of Biosimilars Dr Lincoln Tsang, Arnold and Porter LLP, speaking at BioProcessing, Biologics & Biotherapeutics Congress / Stem Cells Europe 2011.